TREATMENT OF EXCESSIVE NEOVASCULARIZATION

1 . A method of treating an ocular angiogenesis disease caused by excessive neovascularization in the eye of a subject, the method comprising administering to a site characterized by excessive neovascularization in the subject's eye, a cell population comprising STRO-1 bright mesenchymal precursor cells (MPCs) isolated by immunoselection and then culture expanded, wherein there are between 5×10 5 cells/mL and 5×10 7 cells/mL cells in the population at least 1% of which are STRO-1 bright MPCs, so as to reduce such excessive neovascularization in the subject's eye and thereby treat the ocular angiogenesis disease.

2 - 3 . (canceled)

4 . The method of claim 1 , wherein the ocular angiogenesis disease is selected from the group consisting of diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, and rubeosis.

5 . The method of claim 4 , wherein the ocular angiogenesis disease is macular degeneration or diabetic retinopathy.

6 . The method of claim 5 , wherein the macular degeneration is wet age-related macular degeneration.

7 . The method of claim 1 , wherein the STRO-1 bright MPCs are obtained from bone marrow.

8 . (canceled)

9 . The method of claim 1 , wherein the mesenchymal precursor cells are TNAP + , VCAM-1 + , THY-1 + , STRO-2 + , CD45 + , CD146 + , 3G5 + or any combination thereof.

10 - 11 . (canceled)

12 . The method of claim 1 , wherein at least some of the cells are genetically modified.

13 . The method of claim 1 , wherein the angiogenesis-related disease is an angiogenesis-dependent cancer or a benign tumour, and the cells are used to deliver an anti-cancer agent.

14 . (canceled)

15 . The method of claim 6 , wherein the STRO-1 bright MPCs are obtained from bone marrow.

16 . The method of claim 6 , wherein the stem cells are mesenchymal precursor cells (MPC).

17 . The method of claim 6 , wherein at least some of the cells are genetically modified.